ID   NK-92
AC   CVCL_2142
SY   NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK
DR   BTO; BTO_0003287
DR   CLO; CLO_0008177
DR   EFO; EFO_0022517
DR   AddexBio; C0003026/NA
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2407
DR   BCRC; 60414
DR   BioSample; SAMN03471836
DR   CCRID; 4201HUM-CCTCC00052
DR   CCTCC; GDC0052
DR   Cell_Model_Passport; SIDM01143
DR   Cosmic; 1534874
DR   Cosmic; 1542071
DR   Cosmic; 2025326
DR   Cosmic; 2390215
DR   Cosmic; 2785204
DR   DSMZ; ACC-488
DR   DSMZCellDive; ACC-488
DR   GEO; GSM472001
DR   IPD-IMGT/HLA; 13674
DR   Lonza; 1093
DR   Wikidata; Q17149636
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8152260;
RX   PubMed=9118301;
RX   PubMed=9573023;
RX   PubMed=10365666;
RX   PubMed=10803505;
RX   PubMed=11454312;
RX   PubMed=12850795;
RX   PubMed=16827800;
RX   PubMed=18424763;
RX   PubMed=19194464;
RX   PubMed=20454443;
RX   PubMed=21052088;
RX   PubMed=21570725;
RX   PubMed=25586472;
RX   PubMed=26559813;
RX   PubMed=30054012;
RX   PubMed=31126350;
RX   PubMed=31160637;
RX   PubMed=34349345;
RX   PubMed=36610812;
WW   Info; -; -; https://web.archive.org/web/20211125114549/http://www2.kumc.edu/soalab/LabLinks/cell%20lines/nk92.htm
WW   Info; ATCC; -; https://www.atcc.org/en/support/technical-support/faqs/growth-and-morphology-of-nk-92-cells
WW   Info; ClinicalTrials.gov; NCT00900809; https://clinicaltrials.gov/study/NCT00900809
WW   Info; ClinicalTrials.gov; NCT00990717; https://clinicaltrials.gov/study/NCT00990717
WW   Info; ClinicalTrials.gov; NCT02465957; https://clinicaltrials.gov/study/NCT02465957
WW   Info; Wikipedia; -; https://en.wikipedia.org/wiki/NK-92
WW   Provider; Brink Biologics; -; https://brinkbiologics.com/platform/
CC   Group: Patented cell line.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670.
CC   Population: Caucasian.
CC   Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections.
CC   Characteristics: IL2 dependent.
CC   Characteristics: Does not express FCGR3A/CD16.
CC   Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ=ACC-488).
CC   HLA typing: A*03:01:01,11:01:01; B*07:02:01,44:03:01; C*07:02:01,16:01:01; DPA1*01:03:01,01:03:01; DQB1*06:02:01,06:02:01 (DSMZCellDive=ACC-488).
CC   Sequence variation: Mutation; HGNC; HGNC:882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.
CC   Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
CC   Discontinued: AddexBio; C0003026/NA; true.
CC   Discontinued: BCRC; 60414; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
ST   Source(s): ATCC=CRL-2407; DSMZ=ACC-488; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 14,15
ST   D12S391: 19,22
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D18S51: 12,17
ST   D19S433: 14,15
ST   D1S1656: 12,14
ST   D21S11: 31.2,32
ST   D22S1045: 12,17
ST   D2S1338: 19,20
ST   D2S441: 19,20
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 12,15
ST   DYS391: 12
ST   FGA: 20,22
ST   Penta D: 10,12
ST   Penta E: 12
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,18 (DSMZ=ACC-488; Technion Genomics Center)
ST   vWA: 18 (ATCC=CRL-2407)
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 37
CH   CVCL_W733 ! GFP-CD16-F/F.NK-92
CH   CVCL_W734 ! GFP-CD16-V/V.NK-92
CH   CVCL_IM23 ! haNK
CH   CVCL_VN54 ! laNK
CH   CVCL_C7GQ ! NK-92 clone 1
CH   CVCL_C7GR ! NK-92 clone 2
CH   CVCL_VN56 ! NK-92 GFP
CH   CVCL_VN57 ! NK-92.26.5
CH   CVCL_U271 ! NK-92CI
CH   CVCL_3755 ! NK-92MI
CH   CVCL_B5ZF ! NK92-41BB
CH   CVCL_B5ZE ! NK92-CD16
CH   CVCL_V429 ! NoGFP-CD16.NK92
CH   CVCL_B3PC ! TR-IL2-NK-92
CH   CVCL_E1A9 ! Ubigene NK-92 FCER1G KO
//
RX   PubMed=9573023; DOI=10.1182/blood.V91.10.3850;
RA   Nagashima, Shigeki
RA   Mailliard, Robbie
RA   Kashii, Yoshiro
RA   Reichert, Torsten E.
RA   Herberman, Ronald Bruce
RA   Robbins, Paul
RA   Whiteside, Theresa L.
RT   "Stable transduction of the interleukin-2 gene into human natural
RT   killer cell lines and their phenotypic and functional characterization
RT   in vitro and in vivo.";
RL   Blood 91:3850-3861(1998).
//
RX   PubMed=9118301;
RA   Klingemann, Hans-Georg
RA   Wong, Elaine
RA   Maki, Guitta
RT   "A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from
RT   blood.";
RL   Biol. Blood Marrow Transplant. 2:68-75(1996).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler, Hans Gunther
RA   Matsuo, Yoshinobu
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=10365666; DOI=10.1089/10430349950018030;
RA   Tam, Ying K.
RA   Maki, Guitta
RA   Miyagawa, Blythe
RA   Hennemann, Burkhard
RA   Tonn, Torsten
RA   Klingemann, Hans-Georg
RT   "Characterization of genetically altered, interleukin 2-independent
RT   natural killer cell lines suitable for adoptive cellular
RT   immunotherapy.";
RL   Hum. Gene Ther. 10:1359-1373(1999).
//
RX   PubMed=8152260;
RA   Gong, Jian-Hong
RA   Maki, Guitta
RA   Klingemann, Hans-Georg
RT   "Characterization of a human cell line (NK-92) with phenotypical and
RT   functional characteristics of activated natural killer cells.";
RL   Leukemia 8:652-658(1994).
//
RX   PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392; PMCID=PMC2810560;
RA   Binyamin, Liat
RA   Alpaugh, R. Katherine
RA   Hughes, Tracey L.
RA   Lutz, Charles T.
RA   Campbell, Kerry S.
RA   Weiner, Louis M.
RT   "Blocking NK cell inhibitory self-recognition promotes
RT   antibody-dependent cellular cytotoxicity in a model of anti-lymphoma
RT   therapy.";
RL   J. Immunol. 180:6392-6401(2008).
//
RX   PubMed=12850795; DOI=10.1080/14653240310001523;
RA   Tam, Ying K.
RA   Martinson, Jeffrey A.
RA   Doligosa, K.
RA   Klingemann, Hans-Georg
RT   "Ex vivo expansion of the highly cytotoxic human natural killer-92
RT   cell-line under current good manufacturing practice conditions for
RT   clinical adoptive cellular immunotherapy.";
RL   Cytotherapy 5:259-272(2003).
//
RX   PubMed=26559813; DOI=10.1007/s00262-015-1761-x; PMCID=PMC11029582;
RA   Suck, Garnet
RA   Odendahl, Marcus
RA   Nowakowska, Paulina
RA   Seidl, Christian
RA   Wels, Winfried S.
RA   Klingemann, Hans-Georg
RA   Tonn, Torsten
RT   "NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer
RT   cell-based cancer immunotherapy.";
RL   Cancer Immunol. Immunother. 65:485-492(2016).
//
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal, Javeed
RA   Weisenburger, Dennis D.
RA   Chowdhury, Aparajita
RA   Tsai, Ming-Ying
RA   Srivastava, Gopesh
RA   Greiner, Timothy Charles
RA   Kucuk, Can
RA   Deffenbacher, Karen E.
RA   Vose, Julie Marie
RA   Smith, L.
RA   Au, Wing Yan
RA   Nakamura, Shigeo
RA   Seto, Masao
RA   Delabie, Jan
RA   Berger, Francoise
RA   Loong, Florence
RA   Ko, Young-Hyeh
RA   Sng, Ivy
RA   Liu, X.
RA   Loughran, Thomas P. Jr.
RA   Armitage, James Olen
RA   Chan, Wing-Chung
RG   International Peripheral T-cell Lymphoma Project;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RL   Leukemia 25:348-358(2011).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler, Hans Gunther
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010;
RA   Schnueriger, Alfred
RA   Grau, Roger
RA   Sondermann, Peter
RA   Schreitmueller, Thomas
RA   Marti, Stefan
RA   Zocher, Marcel
RT   "Development of a quantitative, cell-line based assay to measure ADCC
RT   activity mediated by therapeutic antibodies.";
RL   Mol. Immunol. 48:1512-1517(2011).
//
RX   PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911;
RA   Kucuk, Can
RA   Jiang, Bei
RA   Hu, Xiao-Zhou
RA   Zhang, Wen-Yan
RA   Chan, John K.C.
RA   Xiao, Wen-Ming
RA   Lack, Nathan
RA   Alkan, Can
RA   Williams, John C.
RA   Avery, Kendra N.
RA   Kavak, Pynar
RA   Scuto, Anna
RA   Sen, Emel
RA   Gaulard, Philippe
RA   Staudt, Louis Michael
RA   Iqbal, Javeed
RA   Zhang, Wei-Wei
RA   Cornish, Adam
RA   Gong, Qiang
RA   Yang, Qun-Pei
RA   Sun, Hong
RA   d'Amore, Francesco Annibale
RA   Leppa, Sirpa
RA   Liu, Wei-Ping
RA   Fu, Kai
RA   de Leval, Laurence
RA   McKeithan, Timothy W.
RA   Chan, Wing-Chung
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
//
RX   PubMed=31126350; DOI=10.1186/s40425-019-0612-2; PMCID=PMC6534912;
RA   Yang, Hyun Gul
RA   Kang, Moon Cheol
RA   Kim, Tae Yoon
RA   Hwang, Injung
RA   Jin, Hyun Tak
RA   Sung, Young Chul
RA   Eom, Ki-Seong
RA   Kim, Sae Won
RT   "Discovery of a novel natural killer cell line with distinct
RT   immunostimulatory and proliferative potential as an alternative
RT   platform for cancer immunotherapy.";
RL   J. Immunother. Cancer 7:138.1-138.17(2019).
//
RX   PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015; PMCID=PMC6345623;
RA   Gunesch, Justin Tyme
RA   Angelo, Laura S.
RA   Mahapatra, Sanjana
RA   Deering, Raquel Payzant
RA   Kowalko, Johanna E.
RA   Sleiman, Patrick
RA   Tobias, John W.
RA   Monaco-Shawver, Linda
RA   Orange, Jordan Scott
RA   Mace, Emily M.
RT   "Genome-wide analyses and functional profiling of human NK cell
RT   lines.";
RL   Mol. Immunol. 115:64-75(2019).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168;
RA   Uphoff, Cord C.
RA   Denkmann, Sabine A.
RA   Steube, Klaus G.
RA   Drexler, Hans Gunther
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal, Javeed
RA   Kucuk, Can
RA   Deleeuw, Ronald J.
RA   Srivastava, Gopesh
RA   Tam, Wayne
RA   Geng, Hui-Min
RA   Klinkebiel, David L.
RA   Christman, Judith K.
RA   Patel, Kavita N.
RA   Cao, K.
RA   Shen, L.
RA   Dybkaer, Karen
RA   Tsui, Ivy F.L.
RA   Ali, Hesham H.
RA   Shimizu, N.
RA   Au, Wing Yan
RA   Lam, Wan L.
RA   Chan, Wing-Chung
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954;
RA   Liu, Angen
RA   Takakuwa, Tetsuya
RA   Luo, Wen-Juan
RA   Fujita, Shigeki
RA   Aozasa, Katsuyuki
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//
RX   PubMed=11454312; DOI=10.1089/152581601750288975;
RA   Maki, Guitta
RA   Klingemann, Hans-Georg
RA   Martinson, Jeffrey A.
RA   Tam, Ying K.
RT   "Factors regulating the cytotoxic activity of the human natural killer
RT   cell line, NK-92.";
RL   J. Hematother. Stem Cell Res. 10:369-383(2001).
//
RX   PubMed=34349345; DOI=10.1007/s10616-021-00476-1; PMCID=PMC8319282;
RA   Zhao, Hui
RA   Zhou, Zhen-Long
RA   Li, Guang-Meng
RA   Liu, Gang
RA   Lin, Shu-Yin
RA   Chen, Wei
RA   Xiong, Sheng
RT   "An NK cell line (NK92-41BB) expressing high levels of granzyme is
RT   engineered to express the high affinity chimeric genes CD16/CAR.";
RL   Cytotechnology 73:539-553(2021).
//
RX   PubMed=36610812; DOI=10.1016/j.jcyt.2022.12.003;
RA   Klingemann, Hans-Georg
RT   "The NK-92 cell line -- 30 years later: its impact on natural killer cell
RT   research and treatment of cancer.";
RL   Cytotherapy 25:451-457(2023).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier, Hilmar
RA   Pommerenke, Claudia
RA   Dirks, Wilhelm Gerhard
RA   Eberth, Sonja
RA   Koeppel, Max
RA   MacLeod, Roderick A.F.
RA   Nagel, Stefan
RA   Steube, Klaus G.
RA   Uphoff, Cord C.
RA   Drexler, Hans Gunther
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218.1-8218.14(2019).
//